Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Importance of the Conserved Carboxyl-Terminal CNOT1 Binding Domain to Tristetraprolin Activity In Vivo.

Lai WS, Stumpo DJ, Wells ML, Gruzdev A, Hicks SN, Nicholson CO, Yang Z, Faccio R, Webster MW, Passmore LA, Blackshear PJ.

Mol Cell Biol. 2019 Jun 13;39(13). pii: e00029-19. doi: 10.1128/MCB.00029-19. Print 2019 Jul 1.

PMID:
31036567
2.

Characteristics and Outcomes of Patients With Severe Aortic Stenosis Discussed by the Multidisciplinary "Heart Team" According to Treatment Allocation.

Rea CW, Wang TKM, Ruygrok PN, Sidhu K, Ramanathan T, Nand P, Stewart JT, Webster MWI.

Heart Lung Circ. 2019 Mar 14. pii: S1443-9506(19)30273-2. doi: 10.1016/j.hlc.2019.02.192. [Epub ahead of print]

PMID:
30948328
3.

RNA-binding proteins distinguish between similar sequence motifs to promote targeted deadenylation by Ccr4-Not.

Webster MW, Stowell JA, Passmore LA.

Elife. 2019 Jan 2;8. pii: e40670. doi: 10.7554/eLife.40670.

4.

Postdischarge outcome after Takotsubo syndrome compared with patients post-ACS and those without prior CVD: ANZACS-QI 19.

Looi JL, Lee M, Webster MWI, To ACY, Kerr AJ.

Open Heart. 2018 Nov 26;5(2):e000918. doi: 10.1136/openhrt-2018-000918. eCollection 2018.

5.

Surgical aortic valve replacement for valve-in-valve trans-catheter aortic valve dysfunction in the patient with a small aortic annulus.

Beliaev AM, Webster MW, Greaves SC, Stewart JT, Haydock DA.

N Z Med J. 2018 Oct 5;131(1483):66-69. No abstract available.

PMID:
30286068
6.

mRNA Deadenylation Is Coupled to Translation Rates by the Differential Activities of Ccr4-Not Nucleases.

Webster MW, Chen YH, Stowell JAW, Alhusaini N, Sweet T, Graveley BR, Coller J, Passmore LA.

Mol Cell. 2018 Jun 21;70(6):1089-1100.e8. doi: 10.1016/j.molcel.2018.05.033.

7.

It seemed like a good idea at the time.

Ormiston JA, Webster MW.

EuroIntervention. 2018 Mar 20;13(16):1876-1879. doi: 10.4244/EIJV13I16A306. No abstract available.

8.

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.

Webster MWI, Stables RH.

N Engl J Med. 2018 Jan 18;378(3):299. doi: 10.1056/NEJMc1714520. No abstract available.

PMID:
29345444
9.

Coronary balloon catheter tip damage. A bench study of a clinical problem.

Barkholt TØ, Ormiston JA, Ding P, Webber B, Ubod B, Waite S, Webster MW.

Catheter Cardiovasc Interv. 2018 Nov 1;92(5):883-889. doi: 10.1002/ccd.27441. Epub 2017 Dec 8.

10.

Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club.

Ormiston JA, Kassab G, Finet G, Chatzizisis YS, Foin N, Mickley TJ, Chiastra C, Murasato Y, Hikichi Y, Wentzel JJ, Darremont O, Iwasaki K, Lefèvre T, Louvard Y, Beier S, Hojeibane H, Netravali A, Wooton J, Cowan B, Webster MW, Medrano-Gracia P, Stankovic G.

EuroIntervention. 2018 Feb 2;13(15):e1794-e1803. doi: 10.4244/EIJ-D-17-00270.

11.

Long and short of optimal stent design.

Watson T, Webster MWI, Ormiston JA, Ruygrok PN, Stewart JT.

Open Heart. 2017 Oct 30;4(2):e000680. doi: 10.1136/openhrt-2017-000680. eCollection 2017. Review.

12.

Analysis of mRNA deadenylation by multi-protein complexes.

Webster MW, Stowell JAW, Tang TTL, Passmore LA.

Methods. 2017 Aug 15;126:95-104. doi: 10.1016/j.ymeth.2017.06.009. Epub 2017 Jun 13.

13.

Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.

Worthley SG, Wilkins GT, Webster MW, Montarello JK, Delacroix S, Whitbourn RJ, Warren RJ.

Atherosclerosis. 2017 Jul;262:94-100. doi: 10.1016/j.atherosclerosis.2017.04.022. Epub 2017 May 3.

14.

Reconstitution of Targeted Deadenylation by the Ccr4-Not Complex and the YTH Domain Protein Mmi1.

Stowell JAW, Webster MW, Kögel A, Wolf J, Shelley KL, Passmore LA.

Cell Rep. 2016 Nov 15;17(8):1978-1989. doi: 10.1016/j.celrep.2016.10.066.

15.

Of Stents and Scaffolds: Trial Data and the Real World.

Ormiston JA, Webster MW.

Circ Cardiovasc Interv. 2016 Aug;9(8). pii: e004249. doi: 10.1161/CIRCINTERVENTIONS.116.004249. No abstract available.

PMID:
27512086
16.

Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance Transporter.

Richards SN, Nash MN, Baker ES, Webster MW, Lehane AM, Shafik SH, Martin RE.

PLoS Pathog. 2016 Jul 21;12(7):e1005725. doi: 10.1371/journal.ppat.1005725. eCollection 2016 Jul.

17.

The yeast transcription elongation factor Spt4/5 is a sequence-specific RNA binding protein.

Blythe AJ, Yazar-Klosinski B, Webster MW, Chen E, Vandevenne M, Bendak K, Mackay JP, Hartzog GA, Vrielink A.

Protein Sci. 2016 Sep;25(9):1710-21. doi: 10.1002/pro.2976. Epub 2016 Jul 15.

18.

Dynamically scaled phantom phase contrast MRI compared to true-scale computational modeling of coronary artery flow.

Beier S, Ormiston JA, Webster MW, Cater JE, Norris SE, Medrano-Gracia P, Young AA, Cowan BR.

J Magn Reson Imaging. 2016 Oct;44(4):983-92. doi: 10.1002/jmri.25240. Epub 2016 Apr 4.

PMID:
27042817
19.

Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis.

Campos CM, Garcia-Garcia HM, Muramatsu T, de Araujo Gonçalves P, Onuma Y, Dudek D, Thuesen L, Webster MW, Kitslaar P, Veldhof S, Reiber JH, Nieman K, Ormiston JA, Serruys PW.

Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):109-16. doi: 10.1016/j.rec.2015.07.027. Epub 2015 Dec 28.

PMID:
26739828
20.

The utility of a 'non-significant' coronary angiogram.

Wang TK, Oh TH, Samaranayake CB, Webster MW, Stewart JT, Watson T, Ellis C, Ruygrok PN.

Int J Clin Pract. 2015 Dec;69(12):1465-72. doi: 10.1111/ijcp.12723. Epub 2015 Aug 25.

PMID:
26304046
21.

Primary PCI with or without Thrombectomy.

Watson T, Webster MW, Ormiston JA.

N Engl J Med. 2015 Aug 13;373(7):681-2. doi: 10.1056/NEJMc1507110. No abstract available.

PMID:
26267634
22.

An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition).

Ormiston JA, Webber B, Ubod B, Darremont O, Webster MW.

EuroIntervention. 2015 May;11(1):60-7. doi: 10.4244/EIJY15M02_03.

23.

Drug-eluting stents--SORTed.

Webster MW, Ormiston JA.

Lancet. 2015 Apr 18;385(9977):1487-9. doi: 10.1016/S0140-6736(14)62009-2. Epub 2015 Jan 16. No abstract available.

PMID:
25601787
24.

Coronary stent durability and fracture: an independent bench comparison of six contemporary designs using a repetitive bend test.

Ormiston JA, Webber B, Ubod B, White J, Webster MW.

EuroIntervention. 2015 Apr;10(12):1449-55. doi: 10.4244/EIJY14M11_08.

25.

The identification and structure of an N-terminal PR domain show that FOG1 is a member of the PRDM family of proteins.

Clifton MK, Westman BJ, Thong SY, O'Connell MR, Webster MW, Shepherd NE, Quinlan KG, Crossley M, Blobel GA, Mackay JP.

PLoS One. 2014 Aug 27;9(8):e106011. doi: 10.1371/journal.pone.0106011. eCollection 2014.

26.

Strut fracture with contemporary stent platforms.

White JM, Webster MW, Ormiston JA.

Catheter Cardiovasc Interv. 2015 Apr;85(5):932. doi: 10.1002/ccd.25551. Epub 2014 Jun 17. No abstract available.

PMID:
24846648
27.

Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies.

Ormiston JA, Webber B, Ubod B, Webster MW, White J.

EuroIntervention. 2015 Feb;10(10):1169-77. doi: 10.4244/EIJY14M05_08.

28.

High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction.

Wang TK, Snow TA, Chen Y, Rostom H, White JM, Stewart JT, Webster MW, Ruygrok PN, Watson T, White HD.

Eur Heart J Acute Cardiovasc Care. 2014 Jun;3(2):118-25. doi: 10.1177/2048872614527006. Epub 2014 Feb 27.

PMID:
24576774
29.

Stent longitudinal strength assessed using point compression: insights from a second-generation, clinically related bench test.

Ormiston JA, Webber B, Ubod B, White J, Webster MW.

Circ Cardiovasc Interv. 2014 Feb;7(1):62-9. doi: 10.1161/CIRCINTERVENTIONS.113.000621. Epub 2013 Dec 24.

PMID:
24368821
30.

How to do it?: percutaneous treatment of a severely stenosed and calcified left main stem bifurcation.

Watson T, Stewart JT, Webster MW.

Heart Lung Circ. 2014 Feb;23(2):177-80. doi: 10.1016/j.hlc.2013.04.123. Epub 2013 May 31.

PMID:
23731981
31.

Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.

Ormiston JA, Watson T, van Pelt N, Stewart R, Stewart JT, White JM, Doughty RN, Stewart F, Macdonald R, Webster MW.

EuroIntervention. 2013 May 20;9(1):70-4. doi: 10.4244/EIJV9I1A11.

32.

Routine cardiac catheterization and angioplasty in anticoagulated patients: does warfarin need to be discontinued?

Snow TA, Wang TK, Watson T, Stewart JT, Webster MW, Ruygrok PN.

Int J Cardiol. 2013 Oct 3;168(3):2976-7. doi: 10.1016/j.ijcard.2013.04.109. Epub 2013 Apr 30. No abstract available.

PMID:
23642602
33.

Do echocardiographic parameters predict mortality in patients with end-stage renal disease?

Stallworthy EJ, Pilmore HL, Webster MW, Sidhu KK, Curry EM, Brown P, Scaria A.

Transplantation. 2013 May 27;95(10):1225-32. doi: 10.1097/TP.0b013e31828dbbbe.

PMID:
23542473
34.

Choice of appropriate endpoints for a balloon versus stent trial.

White JM, Webster MW, Ormiston JA.

J Am Coll Cardiol. 2013 Apr 30;61(17):1831. doi: 10.1016/j.jacc.2012.12.040. No abstract available.

35.

First-in-human use of the OneShot™ renal denervation system from Covidien.

Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, Webster MW.

EuroIntervention. 2013 Jan 22;8(9):1090-4. doi: 10.4244/EIJV8I9A166.

36.

Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.

Ormiston JA, Charles O, Mann T, Hall JJ, McGarry T, Cannon LA, Webster MW, Mishkel GJ, Underwood PL, Dawkins KD.

Coron Artery Dis. 2013 Jan;24(1):61-8. doi: 10.1097/MCA.0b013e32835b3932.

PMID:
23232250
37.

Safety and feasibility of patient transfer by helicopter for primary percutaneous coronary intervention.

White JM, Howard R, Goldsmith R, Harrison N, Johanson SP, Webster MW, Stewart JT, Ormiston JA, Ruygrok PN.

N Z Med J. 2012 Sep 21;125(1362):47-59.

PMID:
23178604
38.

Stent thrombosis: has the firestorm been extinguished?

Ormiston JA, Webster MW.

Lancet. 2012 Apr 14;379(9824):1368-9. doi: 10.1016/S0140-6736(12)60440-1. Epub 2012 Mar 23. No abstract available.

PMID:
22445240
39.

Stent longitudinal integrity bench insights into a clinical problem.

Ormiston JA, Webber B, Webster MW.

JACC Cardiovasc Interv. 2011 Dec;4(12):1310-7. doi: 10.1016/j.jcin.2011.11.002. Epub 2011 Nov 30.

40.

Bioresorbable polymeric vascular scaffolds: a cautionary tale.

Ormiston JA, De Vroey F, Serruys PW, Webster MW.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):535-8. doi: 10.1161/CIRCINTERVENTIONS.111.963710. No abstract available.

PMID:
22010192
41.

The Petal dedicated bifurcation stent.

Ormiston JA, De Vroey F, Webster MW, Kandzari DE.

EuroIntervention. 2010 Dec;6 Suppl J:J139-42. doi: 10.4244/EIJV6SUPJA23. No abstract available.

PMID:
21930479
42.

Clinical practice and implications of recent diabetes trials.

Webster MW.

Curr Opin Cardiol. 2011 Jul;26(4):288-93. doi: 10.1097/HCO.0b013e328347b139. Review.

PMID:
21577100
43.

Nonstandard Programs: the University of Pittsburgh Medical Center's next frontier in graduate medical education.

Kroboth FJ, Zerega WD, Patel RM, Barnes BE, Webster MW.

Acad Med. 2011 Feb;86(2):180-6. doi: 10.1097/ACM.0b013e31820465c6.

PMID:
21169779
44.

Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents.

Weissman NJ, Turco MA, Ormiston JA, Mann T, Cannon LA, McGarry TF, Webster MW, Hall JJ, Lucca MJ, Mishkel GJ, Wu CJ, Mandinov L, Dawkins KD.

Cardiovasc Revasc Med. 2011 Jul-Aug;12(4):247-57. doi: 10.1016/j.carrev.2010.09.008. Epub 2010 Dec 3.

PMID:
21130708
45.

Very late stent malapposition: the apparent legacy of first generation drug-eluting stent technology.

Johnson TW, Kay IP, Ormiston JA, Webster MW.

EuroIntervention. 2010 Jun;6(2):290-1. doi: 10.4244/. No abstract available.

PMID:
20562085
46.

Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.

Bruining N, de Winter S, Roelandt JR, Regar E, Heller I, van Domburg RT, Hamers R, Onuma Y, Dudek D, Webster MW, Thuesen L, Ormiston JA, Cheong WF, Miquel-Hebert K, Veldhof S, Serruys PW.

JACC Cardiovasc Interv. 2010 Apr;3(4):449-56. doi: 10.1016/j.jcin.2010.02.004.

47.

Sorting out drug-eluting stents.

Webster MW, Ormiston JA.

Lancet. 2010 Mar 27;375(9720):1060-2. doi: 10.1016/S0140-6736(10)60402-3. Epub 2010 Mar 16. No abstract available.

PMID:
20231035
48.

Consider charity with caution.

Johnson TW, Occleshaw C, Webster MW.

J Cardiovasc Comput Tomogr. 2010 Jan-Feb;4(1):73-4. doi: 10.1016/j.jcct.2009.10.015. Epub 2009 Nov 27.

PMID:
20159633
49.

HORIZONS-AMI.

Webster MW.

Lancet. 2010 Jan 30;375(9712):375. doi: 10.1016/S0140-6736(10)60163-8. No abstract available.

PMID:
20113821
50.

Noncardiac surgery and bleeding after percutaneous coronary intervention.

To AC, Armstrong G, Zeng I, Webster MW.

Circ Cardiovasc Interv. 2009 Jun;2(3):213-21. doi: 10.1161/CIRCINTERVENTIONS.108.830158. Epub 2009 Apr 21.

PMID:
20031718

Supplemental Content

Loading ...
Support Center